Next Article in Journal
Identification of a Ribose-Phosphate Pyrophosphokinase that Can Interact In Vivo with the Anaphase Promoting Complex/Cyclosome
Next Article in Special Issue
Rethinking the Epigenetic Framework to Unravel the Molecular Pathology of Schizophrenia
Previous Article in Journal
Oxidative Stress-Induced Afterdepolarizations and Protein Kinase C Signaling
Previous Article in Special Issue
A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia

Theranostic Biomarkers for Schizophrenia

Rudjer Boskovic Institute, Division of Molecular Medicine, 10000 Zagreb, Croatia
Clinic for Psychiatry Vrapce, 10090 Zagreb, Croatia
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Yong-Ku Kim
Int. J. Mol. Sci. 2017, 18(4), 733;
Received: 28 February 2017 / Revised: 23 March 2017 / Accepted: 27 March 2017 / Published: 30 March 2017
Schizophrenia is a highly heritable, chronic, severe, disabling neurodevelopmental brain disorder with a heterogeneous genetic and neurobiological background, which is still poorly understood. To allow better diagnostic procedures and therapeutic strategies in schizophrenia patients, use of easy accessible biomarkers is suggested. The most frequently used biomarkers in schizophrenia are those associated with the neuroimmune and neuroendocrine system, metabolism, different neurotransmitter systems and neurotrophic factors. However, there are still no validated and reliable biomarkers in clinical use for schizophrenia. This review will address potential biomarkers in schizophrenia. It will discuss biomarkers in schizophrenia and propose the use of specific blood-based panels that will include a set of markers associated with immune processes, metabolic disorders, and neuroendocrine/neurotrophin/neurotransmitter alterations. The combination of different markers, or complex multi-marker panels, might help in the discrimination of patients with different underlying pathologies and in the better classification of the more homogenous groups. Therefore, the development of the diagnostic, prognostic and theranostic biomarkers is an urgent and an unmet need in psychiatry, with the aim of improving diagnosis, therapy monitoring, prediction of treatment outcome and focus on the personal medicine approach in order to improve the quality of life in patients with schizophrenia and decrease health costs worldwide. View Full-Text
Keywords: schizophrenia; biomarkers; diagnostic; prognostic and theranostic biomarkers; inflammatory; stress-related; metabolic; neurotrophic and neurotransmitter biomarkers schizophrenia; biomarkers; diagnostic; prognostic and theranostic biomarkers; inflammatory; stress-related; metabolic; neurotrophic and neurotransmitter biomarkers
Show Figures

Graphical abstract

MDPI and ACS Style

Perkovic, M.N.; Erjavec, G.N.; Strac, D.S.; Uzun, S.; Kozumplik, O.; Pivac, N. Theranostic Biomarkers for Schizophrenia. Int. J. Mol. Sci. 2017, 18, 733.

AMA Style

Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N. Theranostic Biomarkers for Schizophrenia. International Journal of Molecular Sciences. 2017; 18(4):733.

Chicago/Turabian Style

Perkovic, Matea N., Gordana N. Erjavec, Dubravka S. Strac, Suzana Uzun, Oliver Kozumplik, and Nela Pivac. 2017. "Theranostic Biomarkers for Schizophrenia" International Journal of Molecular Sciences 18, no. 4: 733.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop